Analysts Target Big Gains For These 2 FAANG Stocks

Netflix and Amazon stocks garnered new bullish price targets this morning

Oct 24, 2017 at 10:04 AM
facebook twitter linkedin


Analysts are weighing in on biotech Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN), TV streaming service Netflix, Inc. (NASDAQ:NFLX), and online retail giant Amazon.com, Inc. (NASDAQ:AMZN). Here's a quick roundup of today's bullish brokerage notes on shares of ALXN, NFLX, and AMZN.

Alexion Pharmaceuticals Stock Pops on FDA Drug Approval

Alexion Pharmaceuticals stock is up 4.5% to trade at $141.27, after the U.S. Food and Drug Administration (FDA) approved the biotech's muscle disorder drug Soliris. As a result, RBC upped its price target on ALXN to $166 from $161 -- territory the shares haven't visited since January 2016.

Other analysts are optimistic about the security's price action, too. Of the 16 brokerage firms following ALXN, 13 rate it  a "buy" or better, with not one single "sell" in sight.

Though the security touched a roughly three-year low of $96.18 in late May, it has since climbed roughly 46% to trade back above its 80-day moving average. The shares now boast a 10.5% year-to-date lead.

Cantor Fitzgerald Ups Netflix Stock Price Target

Shares of Netflix stock were last seen trading 0.6% higher at $193.71, after Cantor Fitzgerald raised its price target to $235 from $205 -- in uncharted territory. NFLX shares have surged the charts in 2017, adding roughly 56%. The security hit an all-time high of $204.38 one week ago, and there's room for more analysts to upwardly revise their outlooks for Netflix. Of the 34 brokerages covering the shares, 13 maintain a "hold" or "strong sell" rating.

Analyst Predicts Records Highs For Amazon Stock

Another FAANG stock on the rise this morning is Amazon, last seen up 0.3% at $969.27, after J.P. Morgan Securities boosted its price target to $1,180 from $1,175 -- a roughly 22% premium to current trading levels. AMZN shares have tacked on 29% this year, and hit a record high of $1,083.31 in late July.

The security's recent pullback from here was neatly contained by its 160-day moving average, and option bulls have been betting on a bigger bounce. Short-term speculators are especially call-skewed, based on the stock's Schaeffer's put/call open interest ratio (SOIR) of 0.95, which ranks in just the 9th percentile of its annual range.

Make the Most of the next Expiration Week Countdown!


 




 
Special Offers from Schaeffer's Trading Partners